SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector
Store in a refrigerator at 36°F to 46° F (2°C to 8°C)
Manufacturer # 00074107001
Brand SKYRIZI®
Manufacturer AbbVie US LLC
Country of Origin Germany
Application Monoclonal Antibody
Container Type Single-Dose Prefilled Cartridge
Dosage Form Injection
Generic Drug Name Risankizumab-rzaa
Is_Active_Vendor Y
Is_DSCSA Y
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 00074107001
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires Refrigeration
Strength 150 mg / mL
Supplier_ID 4384414
Type Subcutaneous
UNSPSC Code 42142619
Volume 2.4 mL
